PIONEERING EARLY CANCER DETECTION & TAILORED TREATMENT PLANS

​

Invest from £12,000

At Frontier Diagnostics, we're not just developing new ways to detect cancer, we're changing the entire approach to how it's monitored, treated, and beaten. Led by industry-renowned biochemist Dr. Martin Burow, former Head of Asia Pacific at Thermo Fisher and a leading global authority on circulating tumour cell research, Frontier has built a precision diagnostics platform that gives oncologists real-time intelligence from a simple blood draw. No invasive biopsy. No waiting months for a scan. Just fast, accurate, personalised data - at the moment it matters most.

• HMRC-approved EIS opportunity offering generous tax breaks
• Shares priced at £1.20. Post-money valuation: £18m
• Raising £3m. Minimum investment: £12,000
• ISO 15189-accredited laboratory. Operational in UK & Europe
• Established distribution partnerships across Southeast Asia
• Forecast £61.75m revenue and £31.5m EBITDA by 2029
• Planned M&A exit Q4 2029. Targeting 10.5x return

• A £1.87bn European cancer diagnostics market growing at 4.8% annually
• Proprietary CTC technology with a clear, scalable path to global clinical adoption
• Already operating in a clinical setting - ISO 15189-accredited lab processing real patient samples with a 5-day turnaround
• Dual revenue model - per-test lab fees plus hardware sales of the Quantum FluoScope device, with recurring consumable income
• Debt-free company backed by a world-class medical advisory board including former Chief Medical Officer of Teva Pharmaceuticals